In The Cancer Letter: “Changes to FDA warn­ings and labeling should be grounded in rigorous, contemporary evidence.”

Your gift is doubled through December 31.

Donate Now

In the latest edition of The Cancer Letter, NBCC’s Chief Programs Officer Michelle Tregear expanded upon NBCC’s recent statement on the Food and Drug Administration (FDA) hormone replacement therapy (HRT) black box warning removal:

We would probably agree that the black box warning was not appropriate for current day uses of the new formula­tions, but you don’t just simply remove those black box warnings… We need to follow the robust, evi­dence-based processes in making these decisions, in part to ensure that people have trust in the decisions that are be­ing made.

Related News